ArticleBMC microbiology2025
Enhanced antibacterial activity of 3D-printed niosome-curcumin/ceftizoxime scaffolds against drug-resistant pathogens.
Article in BMC microbiology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Caerin 1.1/1.9 Inhibits Growth and Biofilm Formation of Carbapenem-Resistant Klebsiella pneumoniae and Induces Coordinated Transcriptomic Stress Responses.Current microbiology · 2026Article
- Article
- Detection to Disruption: A Comprehensive Review of Bacterial Biofilms and Therapeutic Advances.Antibiotics (Basel, Switzerland) · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Hospital-acquired infections caused by multidrug-resistant (MDR) pathogens such as Methicillin-resistant Staphylococcus aureus (MRSA) and Carbapenem-resistant Klebsiella pneumoniae (CRKP) are a major health concern. In this study, ceftizoxime (CEF) and curcumin (CUR) were co-encapsulated into niosome nanoparticles (using thin-film hydration), and then embedded into a 3D-printed gelatin-alginate scaffold (Nio-CUR/CEF@SC). The Nio-CUR/CEF@SC were characterized by dynamic light scattering (DLS), transmission electron microscopy (TEM), scanning electron microscopy (SEM), and Fourier-transform infrared spectroscopy (FTIR). The antibacterial activity was assessed using MIC, time-kill, and disc diffusion assays, while anti-biofilm activity was evaluated using crystal violet (CV) and minimum biofilm eradication concentration (MBEC) assays. Gene expression of virulence and resistance genes was measured using qRT-PCR, and cytotoxicity was tested via MTT assay on HFF cells. The Nio-CUR/CEF@SC system exhibited high encapsulation efficiency (CUR:78%; CEF: 80%), uniform nanoscale size (208–308 nm), and sustained dual-drug release over 72 h. This formulation reduced MIC values against MRSA and CRKP to 0.25–1 µg/mL (over 64-fold improvement vs. free drugs), produced large inhibition zones (up to 31.5 mm), and achieved strong time-kill and anti-biofilm effects (> 2 log₁₀ CFU/mL reduction). It also led to significant downregulation of MRSA ((hla, hlb, pvl)_ and CRKP (blaTEM, blaCTXM, blaOXA-48) virulence/resistance genes and showed > 90% viability on normal fibroblasts at effective doses. This study demonstrates that 3D-printed Nio-CUR/CEF@SC is an effective drug delivery system for the treatment of MRSA and CRKP infections in vitro. The engineered nanocarrier has potential for further research on infection therapies and offers a promising approach to combat drug-resistant pathogens.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.